American Association for Cancer Research
Browse (415.61 kB)

Supplementary Figure 1 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity

Download (415.61 kB)
posted on 2023-04-03, 14:24 authored by Jae-Cheol Jo, Eun Kyoung Choi, Jae-Sik Shin, Jai-Hee Moon, Seung-Woo Hong, Ha-Reum Lee, Seung-Mi Kim, Soo-A Jung, Dae-Hee Lee, Seang Hwan Jung, Sun-Hye Lee, Jeong Eun Kim, Kyu-pyo Kim, Yong Sang Hong, Young-Ah Suh, Se Jin Jang, Eun Kyung Choi, Jung Shin Lee, Dong-Hoon Jin, Tae Won Kim

Inhibition of cell growth and downstream signaling molecules of HCC cell lines by MET or pan-FGFR inhibitor.



The MET receptor tyrosine kinase, the receptor for hepatocyte growth factor (HGF), has been implicated in cancer growth, invasion, migration, angiogenesis, and metastasis in a broad variety of human cancers, including human hepatocellular carcinoma (HCC). Recently, MET was suggested to be a potential target for the personalized treatment of HCC with an active HGF–MET signaling pathway. However, the mechanisms of resistance to MET inhibitors need to be elucidated to provide effective treatment. Here, we show that HCC cells exhibit different sensitivities to the MET inhibitor PHA665752, depending on the phosphorylation status of FGFR. Treatment of cells expressing both phospho-FGFR and phospho-MET with the inhibitor PHA665752 did not cause growth inhibition and cell death, whereas treatment with AZD4547, a pan-FGFR inhibitor, resulted in decreased colony formation and cleavage of caspase-3. Moreover, silencing of endogenous FGFR1 and FGFR2 by RNAi of HCC cells expressing phospho-FGFR, phospho-FGFR2, and phospho-MET overcame the resistance to PHA665752 treatment. Treatment of primary cancer cells from patients with HCC expressing both phospho-FGFR and phospho-MET with PHA665752 did not induce cell death, whereas AZD4547 treatment induced cell death through the cleavage of caspase-3. In addition, treatment of cells resistant to PHA665752 with AZD4547 abrogated the activation of downstream effectors of cell growth, proliferation, and survival. On the basis of these results, we conclude that the FGFR pathway is critical for HCC survival, and that targeting this pathway with AZD4547 may be beneficial for the treatment of patients with HCC-expressing phospho-FGFR and phospho-MET. Mol Cancer Ther; 14(11); 2613–22. ©2015 AACR.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager